RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non‐Metastatic Ovarian Cancer in Mice
ABSTRACT Tumor‐ and bone‐derived soluble factors have been proposed to participate in the alterations of skeletal muscle size and function in cachexia. We previously showed that mice bearing ovarian cancer (OvCa) exhibit cachexia associated with marked bone loss, whereas bone‐targeting agents, such...
Gespeichert in:
| Veröffentlicht in: | Journal of bone and mineral research Jg. 37; H. 3; S. 381 - 396 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Hoboken, USA
John Wiley & Sons, Inc
01.03.2022
Oxford University Press |
| Schlagworte: | |
| ISSN: | 0884-0431, 1523-4681, 1523-4681 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | ABSTRACT
Tumor‐ and bone‐derived soluble factors have been proposed to participate in the alterations of skeletal muscle size and function in cachexia. We previously showed that mice bearing ovarian cancer (OvCa) exhibit cachexia associated with marked bone loss, whereas bone‐targeting agents, such as bisphosphonates, are able to preserve muscle mass in animals exposed to anticancer drugs. De‐identified CT images and plasma samples from female patients affected with OvCa were used for body composition assessment and quantification of circulating cross‐linked C‐telopeptide type I (CTX‐I) and receptor activator of NF‐kB ligand (RANKL), respectively. Female mice bearing ES‐2 tumors were used to characterize cancer‐ and RANKL‐associated effects on muscle and bone. Murine C2C12 and human HSMM myotube cultures were used to determine the OvCa‐ and RANKL‐dependent effects on myofiber size. To the extent of isolating new regulators of bone and muscle in cachexia, here we demonstrate that subjects affected with OvCa display evidence of cachexia and increased bone turnover. Similarly, mice carrying OvCa present high RANKL levels. By using in vitro and in vivo experimental models, we found that elevated circulating RANKL is sufficient to cause skeletal muscle atrophy and bone resorption, whereas bone preservation by means of antiresorptive and anti‐RANKL treatments concurrently benefit muscle mass and function in cancer cachexia. Altogether, our data contribute to identifying RANKL as a novel therapeutic target for the treatment of musculoskeletal complications associated with RANKL‐expressing non‐metastatic cancers. © 2021 American Society for Bone and Mineral Research (ASBMR).
RANKL directly impairs muscle mass and function in cancer cachexia.
Tumor‐derived factors, including RANKL, drive bone resorption in non‐bone metastatic cancer.
Blockade of RANKL and cancer‐associated bone resorption results in improved muscle mass and function, even in the absence of bone metastases. |
|---|---|
| AbstractList | Tumor‐ and bone‐derived soluble factors have been proposed to participate in the alterations of skeletal muscle size and function in cachexia. We previously showed that mice bearing ovarian cancer (OvCa) exhibit cachexia associated with marked bone loss, whereas bone‐targeting agents, such as bisphosphonates, are able to preserve muscle mass in animals exposed to anticancer drugs. De‐identified CT images and plasma samples from female patients affected with OvCa were used for body composition assessment and quantification of circulating cross‐linked C‐telopeptide type I (CTX‐I) and receptor activator of NF‐kB ligand (RANKL), respectively. Female mice bearing ES‐2 tumors were used to characterize cancer‐ and RANKL‐associated effects on muscle and bone. Murine C2C12 and human HSMM myotube cultures were used to determine the OvCa‐ and RANKL‐dependent effects on myofiber size. To the extent of isolating new regulators of bone and muscle in cachexia, here we demonstrate that subjects affected with OvCa display evidence of cachexia and increased bone turnover. Similarly, mice carrying OvCa present high RANKL levels. By using in vitro and in vivo experimental models, we found that elevated circulating RANKL is sufficient to cause skeletal muscle atrophy and bone resorption, whereas bone preservation by means of antiresorptive and anti‐RANKL treatments concurrently benefit muscle mass and function in cancer cachexia. Altogether, our data contribute to identifying RANKL as a novel therapeutic target for the treatment of musculoskeletal complications associated with RANKL‐expressing non‐metastatic cancers. © 2021 American Society for Bone and Mineral Research (ASBMR). Tumor- and bone-derived soluble factors have been proposed to participate in the alterations of skeletal muscle size and function in cachexia. We previously showed that mice bearing ovarian cancer (OvCa) exhibit cachexia associated with marked bone loss, whereas bone-targeting agents, such as bisphosphonates, are able to preserve muscle mass in animals exposed to anticancer drugs. De-identified CT images and plasma samples from female patients affected with OvCa were used for body composition assessment and quantification of circulating cross-linked C-telopeptide type I (CTX-I) and receptor activator of NF-kB ligand (RANKL), respectively. Female mice bearing ES-2 tumors were used to characterize cancer- and RANKL-associated effects on muscle and bone. Murine C2C12 and human HSMM myotube cultures were used to determine the OvCa- and RANKL-dependent effects on myofiber size. To the extent of isolating new regulators of bone and muscle in cachexia, here we demonstrate that subjects affected with OvCa display evidence of cachexia and increased bone turnover. Similarly, mice carrying OvCa present high RANKL levels. By using in vitro and in vivo experimental models, we found that elevated circulating RANKL is sufficient to cause skeletal muscle atrophy and bone resorption, whereas bone preservation by means of antiresorptive and anti-RANKL treatments concurrently benefit muscle mass and function in cancer cachexia. Altogether, our data contribute to identifying RANKL as a novel therapeutic target for the treatment of musculoskeletal complications associated with RANKL-expressing non-metastatic cancers. © 2021 American Society for Bone and Mineral Research (ASBMR). Abstract RANKL directly impairs muscle mass and function in cancer cachexia. Tumor-derived factors, including RANKL, drive bone resorption in non-bone metastatic cancer. Blockade of RANKL and cancer-associated bone resorption results in improved muscle mass and function, even in the absence of bone metastases. Tumor- and bone-derived soluble factors have been proposed to participate in the alterations of skeletal muscle size and function in cachexia. We previously showed that mice bearing ovarian cancer (OvCa) exhibit cachexia associated with marked bone loss, whereas bone-targeting agents, such as bisphosphonates, are able to preserve muscle mass in animals exposed to anticancer drugs. De-identified CT images and plasma samples from female patients affected with OvCa were used for body composition assessment and quantification of circulating cross-linked C-telopeptide type I (CTX-I) and receptor activator of NF-kB ligand (RANKL), respectively. Female mice bearing ES-2 tumors were used to characterize cancer- and RANKL-associated effects on muscle and bone. Murine C2C12 and human HSMM myotube cultures were used to determine the OvCa- and RANKL-dependent effects on myofiber size. To the extent of isolating new regulators of bone and muscle in cachexia, here we demonstrate that subjects affected with OvCa display evidence of cachexia and increased bone turnover. Similarly, mice carrying OvCa present high RANKL levels. By using in vitro and in vivo experimental models, we found that elevated circulating RANKL is sufficient to cause skeletal muscle atrophy and bone resorption, whereas bone preservation by means of antiresorptive and anti-RANKL treatments concurrently benefit muscle mass and function in cancer cachexia. Altogether, our data contribute to identifying RANKL as a novel therapeutic target for the treatment of musculoskeletal complications associated with RANKL-expressing non-metastatic cancers. © 2021 American Society for Bone and Mineral Research (ASBMR).Tumor- and bone-derived soluble factors have been proposed to participate in the alterations of skeletal muscle size and function in cachexia. We previously showed that mice bearing ovarian cancer (OvCa) exhibit cachexia associated with marked bone loss, whereas bone-targeting agents, such as bisphosphonates, are able to preserve muscle mass in animals exposed to anticancer drugs. De-identified CT images and plasma samples from female patients affected with OvCa were used for body composition assessment and quantification of circulating cross-linked C-telopeptide type I (CTX-I) and receptor activator of NF-kB ligand (RANKL), respectively. Female mice bearing ES-2 tumors were used to characterize cancer- and RANKL-associated effects on muscle and bone. Murine C2C12 and human HSMM myotube cultures were used to determine the OvCa- and RANKL-dependent effects on myofiber size. To the extent of isolating new regulators of bone and muscle in cachexia, here we demonstrate that subjects affected with OvCa display evidence of cachexia and increased bone turnover. Similarly, mice carrying OvCa present high RANKL levels. By using in vitro and in vivo experimental models, we found that elevated circulating RANKL is sufficient to cause skeletal muscle atrophy and bone resorption, whereas bone preservation by means of antiresorptive and anti-RANKL treatments concurrently benefit muscle mass and function in cancer cachexia. Altogether, our data contribute to identifying RANKL as a novel therapeutic target for the treatment of musculoskeletal complications associated with RANKL-expressing non-metastatic cancers. © 2021 American Society for Bone and Mineral Research (ASBMR). ABSTRACT Tumor‐ and bone‐derived soluble factors have been proposed to participate in the alterations of skeletal muscle size and function in cachexia. We previously showed that mice bearing ovarian cancer (OvCa) exhibit cachexia associated with marked bone loss, whereas bone‐targeting agents, such as bisphosphonates, are able to preserve muscle mass in animals exposed to anticancer drugs. De‐identified CT images and plasma samples from female patients affected with OvCa were used for body composition assessment and quantification of circulating cross‐linked C‐telopeptide type I (CTX‐I) and receptor activator of NF‐kB ligand (RANKL), respectively. Female mice bearing ES‐2 tumors were used to characterize cancer‐ and RANKL‐associated effects on muscle and bone. Murine C2C12 and human HSMM myotube cultures were used to determine the OvCa‐ and RANKL‐dependent effects on myofiber size. To the extent of isolating new regulators of bone and muscle in cachexia, here we demonstrate that subjects affected with OvCa display evidence of cachexia and increased bone turnover. Similarly, mice carrying OvCa present high RANKL levels. By using in vitro and in vivo experimental models, we found that elevated circulating RANKL is sufficient to cause skeletal muscle atrophy and bone resorption, whereas bone preservation by means of antiresorptive and anti‐RANKL treatments concurrently benefit muscle mass and function in cancer cachexia. Altogether, our data contribute to identifying RANKL as a novel therapeutic target for the treatment of musculoskeletal complications associated with RANKL‐expressing non‐metastatic cancers. © 2021 American Society for Bone and Mineral Research (ASBMR). RANKL directly impairs muscle mass and function in cancer cachexia. Tumor‐derived factors, including RANKL, drive bone resorption in non‐bone metastatic cancer. Blockade of RANKL and cancer‐associated bone resorption results in improved muscle mass and function, even in the absence of bone metastases. |
| Author | Bonetto, Andrea Huot, Joshua R Narasimhan, Ashok Bonewald, Lynda F Pin, Fabrizio Jones, Alexander J Zimmers, Teresa A |
| AuthorAffiliation | 2 Department of Otolaryngology-Head & Neck Surgery, Indiana University School of Medicine, Indianapolis, IN, USA 3 Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA 4 Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA 5 Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, IN, USA 1 Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA |
| AuthorAffiliation_xml | – name: 5 Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, IN, USA – name: 2 Department of Otolaryngology-Head & Neck Surgery, Indiana University School of Medicine, Indianapolis, IN, USA – name: 1 Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA – name: 3 Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA – name: 4 Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA |
| Author_xml | – sequence: 1 givenname: Fabrizio surname: Pin fullname: Pin, Fabrizio organization: Indiana University School of Medicine – sequence: 2 givenname: Alexander J orcidid: 0000-0002-9219-285X surname: Jones fullname: Jones, Alexander J organization: Indiana University School of Medicine – sequence: 3 givenname: Joshua R surname: Huot fullname: Huot, Joshua R organization: Indiana University School of Medicine – sequence: 4 givenname: Ashok surname: Narasimhan fullname: Narasimhan, Ashok organization: Indiana University School of Medicine – sequence: 5 givenname: Teresa A surname: Zimmers fullname: Zimmers, Teresa A organization: Indiana University School of Medicine – sequence: 6 givenname: Lynda F surname: Bonewald fullname: Bonewald, Lynda F organization: Indiana University School of Medicine – sequence: 7 givenname: Andrea orcidid: 0000-0002-3235-1871 surname: Bonetto fullname: Bonetto, Andrea email: abonetto@iu.edu organization: Indiana University School of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34904285$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kc1uEzEUhS1URNPCghdAltjAYtrrGc_fBqmJ-CkkrRR1b-54bqjDxG7tmUJ2PALPyJPgoSmCClZe3O8c33vOAduzzhJjTwUcCYD0eN1s_JGUFTxgE5GnWSKLSuyxCVSVTEBmYp8dhLAGgCIvikdsP5M1yLTKJ-zj8uTsw5xPO6c_Y0t8Se2gKfAZ6kv6apCjbfk0fsfnLgR-asdxy5stP3P2x7fvC-ox9Ngbzc9v0Bu0UWo1eW4sXxhNj9nDFXaBnuzeQ3bx5vXF7F0yP397OjuZJ1rKDJJM10Urq5JakDmmJZWUp5ABYLpqsBQNrvISdS0Eyow0ptDGY8pyJSTVmrJD9urW9mpoNtRqsr3HTl15s0G_VQ6N-ntizaX65G5UVctoJKPBi52Bd9cDhV5tTNDUdWjJDUGlRYy6EqKuI_r8Hrp2g7fxukhJqKEsytHw2Z8b_V7lLvsIHN8C2sdoPa2UNmOSblzQdEqAGttVY7tqbDcqXt5T3Jn-i925fzEdbf8PqvfTxfKX4idS_bRP |
| CitedBy_id | crossref_primary_10_1210_endocr_bqad176 crossref_primary_10_1016_j_ccell_2023_02_007 crossref_primary_10_3892_ol_2023_14049 crossref_primary_10_7554_eLife_92263 crossref_primary_10_1016_j_mad_2025_112039 crossref_primary_10_3389_fphys_2022_1032450 crossref_primary_10_1016_j_metabol_2023_155638 crossref_primary_10_3390_cells12111538 crossref_primary_10_3390_ijms26168011 crossref_primary_10_3389_fcell_2022_903657 crossref_primary_10_1007_s11914_024_00890_2 crossref_primary_10_1007_s11914_023_00788_5 crossref_primary_10_1007_s11914_024_00872_4 crossref_primary_10_1002_jcsm_13289 crossref_primary_10_3389_fpain_2025_1514459 crossref_primary_10_7554_eLife_92263_3 crossref_primary_10_1007_s00223_023_01091_2 crossref_primary_10_1007_s00223_023_01093_0 |
| Cites_doi | 10.3389/fendo.2019.00809 10.1002/jcsm.12642 10.1093/bioinformatics/bts731 10.1002/jcsm.12524 10.3322/caac.21590 10.1097/IGC.0000000000000867 10.1038/s41598-017-15040-1 10.1084/jem.20190450 10.1002/jcsm.12311 10.1016/j.cytogfr.2004.06.004 10.1002/jbmr.4021 10.1101/gad.11.24.3482 10.1093/carcin/21.4.585 10.1038/nm.3961 10.1152/ajpcell.00285.2015 10.1210/endrev/bnaa016 10.1093/hmg/ddz312 10.1007/s11914-006-0012-7 10.1093/hmg/ddz124 10.1016/j.clnu.2008.06.013 10.1074/jbc.M010153200 10.1016/j.ygyno.2013.03.003 10.1093/jjco/hyf082 10.1139/H08-075 10.4137/CMO.S8511 10.1371/journal.pone.0138189 10.1172/jci.insight.136687 10.1038/ncomms3126 10.1093/bioinformatics/btw354 10.3389/fcell.2020.00325 10.1042/BSR20160150 10.1002/jbmr.2112 10.1016/S1470-2045(10)70218-7 10.1016/j.bbagen.2012.11.009 10.1007/s10549-005-5991-z 10.1016/j.ejso.2016.12.016 10.5468/ogs.20012 10.1016/j.neo.2017.05.002 10.1007/s11136-007-9215-3 10.1083/jcb.201006098 10.1186/s40478-018-0533-1 10.1074/jbc.M115.642090 10.5535/arm.2019.43.3.314 10.1097/00000421-198212000-00014 10.1056/NEJM197512182932502 10.1016/S0022-5347(05)64985-3 10.3322/caac.21388 10.1093/ajcn/83.6.1345 10.1096/fj.13-245894 10.18632/oncotarget.14139 10.1590/1414-431x20176265 10.1016/j.canlet.2021.06.030 10.1371/journal.pone.0072162 10.1016/j.bone.2011.09.052 10.1002/jcp.22402 10.4158/EP12141.RA 10.4049/jimmunol.1103387 10.1016/j.ctrv.2019.05.003 10.1002/jbmr.2162 10.1359/jbmr.2000.15.7.1321 10.1093/bioinformatics/btt656 10.1016/S0090-4295(99)00301-5 10.1359/jbmr.081112 10.1093/nar/30.1.207 10.1172/JCI125915 10.3389/fendo.2019.00543 10.1038/nature04524 10.1126/science.3616618 10.1093/bioinformatics/btp616 10.1172/JCI6800 10.1016/j.ygyno.2015.05.040 10.1084/jem.188.5.997 10.1196/annals.1443.016 10.3390/cancers11060791 10.1097/IGC.0000000000001157 10.1093/bioinformatics/bts635 |
| ContentType | Journal Article |
| Copyright | 2021 American Society for Bone and Mineral Research (ASBMR). 2022 American Society for Bone and Mineral Research |
| Copyright_xml | – notice: 2021 American Society for Bone and Mineral Research (ASBMR). – notice: 2022 American Society for Bone and Mineral Research |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7TS K9. 7X8 5PM |
| DOI | 10.1002/jbmr.4480 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Physical Education Index ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Calcium & Calcified Tissue Abstracts Physical Education Index MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) CrossRef MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| EISSN | 1523-4681 |
| EndPage | 396 |
| ExternalDocumentID | PMC8940654 34904285 10_1002_jbmr_4480 JBMR4480 |
| Genre | article Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: National Institute of Aging funderid: PO1AG039355 – fundername: Ralph W. and Grace M. Showalter Research Trust Fund – fundername: Lustgarten Foundation – fundername: Veterans Administration funderid: 1I01‐BX004177‐01 – fundername: National Cancer Institute funderid: R01CA122596; R01CA194593 – fundername: National Institute of Arthritis and Musculoskeletal and Skin Diseases funderid: R01AR079379 – fundername: American Cancer Society funderid: 132013‐RSG‐18‐010‐01‐CCG – fundername: NCI NIH HHS grantid: P30 CA082709 – fundername: NCI NIH HHS grantid: R01CA194593 – fundername: NIA NIH HHS grantid: P01 AG039355 – fundername: NIAMS NIH HHS grantid: R01 AR079379 – fundername: NCI NIH HHS grantid: R01CA122596 – fundername: NCI NIH HHS grantid: R01 CA194593 – fundername: BLRD VA grantid: I01 BX004177 – fundername: NCI NIH HHS grantid: R01 CA122596 – fundername: NIAMS NIH HHS grantid: T32 AR065971 – fundername: NIA NIH HHS grantid: PO1AG039355 |
| GroupedDBID | --- .55 .GJ 05W 0R~ 1OB 1OC 24P 29K 2WC 31~ 33P 3SF 3WU 4.4 50Y 52U 53G 5GY 5RE 5WD 66C 8-0 8-1 A00 AAESR AAEVG AAHHS AANHP AANLZ AAONW AASGY AAUAY AAXRX AAYCA AAZKR ABCUV ABDFA ABEFU ABEJV ABJNI ABNHQ ABQNK ABXGK ABXVV ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACXBN ACXQS ACYXJ ACZBC ADBTR ADEOM ADIPN ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFGKR AFPWT AFWVQ AFZJQ AGMDO AHMBA AHMMS AIACR AIURR AIWBW AJAOE AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVNTJ AVWKF AZBYB AZFZN AZVAB BCRHZ BDRZF BFHJK BHBCM BMXJE BNHUX BOGZA BQCPF BRXPI CS3 D-I DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN F5P FEDTE FUBAC G-S GK1 GODZA HVGLF HZ~ IJI IX1 KBYEO LATKE LEEKS LITHE LOXES LUTES LYRES MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ NNB O66 O9- OCZFY OJZSN OK1 OVD OWPYF P2P P2W P4E PALCI PQQKQ R.K RIG RIWAO RJQFR ROL ROX RWI RX1 SJN SUPJJ TEORI TR2 VJK W99 WBKPD WIH WIJ WIK WNSPC WOHZO WYISQ WYJ X7M XV2 ZGI ZXP ZZTAW ~S- AAMMB AAYXX ABGNP AEFGJ AGXDD AIDQK AIDYY AJNCP CITATION KOP WIN ACVCV AFFQV AGORE AGQPQ AHGBF AJBYB AJDVS CGR CUY CVF ECM EIF NPM 7QP 7TS K9. 7X8 5PM |
| ID | FETCH-LOGICAL-c4430-3c96d487ed045a27e7e520300a2fba71baf57ac911a43eca20d06577f14e9ce3 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 22 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000729624000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0884-0431 1523-4681 |
| IngestDate | Tue Sep 30 17:16:50 EDT 2025 Thu Oct 02 12:08:24 EDT 2025 Tue Oct 07 06:05:39 EDT 2025 Mon Jul 21 05:45:07 EDT 2025 Tue Nov 18 22:12:17 EST 2025 Sat Nov 29 06:19:10 EST 2025 Wed Jan 22 16:25:38 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | MUSCLE CACHEXIA RANKL BONE ANTIRESORPTIVE TREATMENTS CANCER |
| Language | English |
| License | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model 2021 American Society for Bone and Mineral Research (ASBMR). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4430-3c96d487ed045a27e7e520300a2fba71baf57ac911a43eca20d06577f14e9ce3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Author contribution FP, LFB and AB conceived and designed the experiments; FP and JRH performed the in vitro and in vivo experiments and molecular characterization of cachexia in OvCa patients and in mice; AJJ performed the body composition analysis in the CT scans from OvCa patients; FP, AN, TAZ and AB analyzed the RNA sequencing data; FP, TAZ, LFB and AB, wrote and edited the paper. |
| ORCID | 0000-0002-9219-285X 0000-0002-3235-1871 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jbmr.4480 |
| PMID | 34904285 |
| PQID | 2640907674 |
| PQPubID | 1006376 |
| PageCount | 16 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8940654 proquest_miscellaneous_2610081199 proquest_journals_2640907674 pubmed_primary_34904285 crossref_citationtrail_10_1002_jbmr_4480 crossref_primary_10_1002_jbmr_4480 wiley_primary_10_1002_jbmr_4480_JBMR4480 |
| PublicationCentury | 2000 |
| PublicationDate | March 2022 |
| PublicationDateYYYYMMDD | 2022-03-01 |
| PublicationDate_xml | – month: 03 year: 2022 text: March 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | Hoboken, USA |
| PublicationPlace_xml | – name: Hoboken, USA – name: United States – name: Baltimore |
| PublicationTitle | Journal of bone and mineral research |
| PublicationTitleAlternate | J Bone Miner Res |
| PublicationYear | 2022 |
| Publisher | John Wiley & Sons, Inc Oxford University Press |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: Oxford University Press |
| References | 2013; 29 2017; 7 2017; 8 2013; 4 2021; 520 2020; 63 2019; 11 2019; 10 2017; 43 2013; 129 2016; 32 2016; 30 2012; 18 2011; 12 2008; 33 2020; 11 2014; 29 2019; 129 2014; 28 2013; 8 2016; 36 2020; 8 2018; 6 2018; 9 2020; 5 2010; 26 2015; 290 1987; 237 1997; 11 2015; 138 2000; 15 1982; 5 2008; 27 2019; 28 2016; 310 2006; 440 1999; 54 2010; 191 2018; 28 2009; 24 2013; 1830 2012; 189 2002; 30 2020; 41 2017; 27 2019; 76 2000; 21 2002; 32 2017; 67 2015; 10 1975; 293 2020; 35 2006; 4 1999; 104 2001; 21 2007; 16 2011; 226 2008; 1143 2012; 50 2001; 276 2016; 7 2006; 83 2019; 43 2020; 70 2004; 15 2017; 10 2021; 218 2015; 21 2002; 167 1983; 43 2017; 19 2018; 51 2005; 94 1998; 188 2014; 30 2012; 6 2020; 29 Dufresne (2024012714033572800_jbmr4480-bib-0017) 2016; 310 Suva (2024012714033572800_jbmr4480-bib-0061) 1987; 237 Pin (2024012714033572800_jbmr4480-bib-0012) 2018; 9 Renema (2024012714033572800_jbmr4480-bib-0073) 2016; 36 Oken (2024012714033572800_jbmr4480-bib-0031) 1982; 5 Rupert (2024012714033572800_jbmr4480-bib-0069) 2021; 218 Wei (2024012714033572800_jbmr4480-bib-0056) 1999; 54 Bonnet (2024012714033572800_jbmr4480-bib-0027) 2019; 129 Rinotas (2024012714033572800_jbmr4480-bib-0075) 2014; 29 Fontes-Oliveira (2024012714033572800_jbmr4480-bib-0041) 2013; 1830 Hung (2024012714033572800_jbmr4480-bib-0058) 2002; 32 Bonetto (2024012714033572800_jbmr4480-bib-0013) 2016; 7 Dobin (2024012714033572800_jbmr4480-bib-0043) 2013; 29 Bronger (2024012714033572800_jbmr4480-bib-0002) 2017; 27 Evans (2024012714033572800_jbmr4480-bib-0033) 2008; 27 Paul (2024012714033572800_jbmr4480-bib-0029) 2010; 191 Collin-Osdoby (2024012714033572800_jbmr4480-bib-0072) 2001; 276 Wieser (2024012714033572800_jbmr4480-bib-0018) 2019; 11 Cheung (2024012714033572800_jbmr4480-bib-0050) 2012; 50 Franzoso (2024012714033572800_jbmr4480-bib-0080) 1997; 11 Xiong (2024012714033572800_jbmr4480-bib-0070) 2015; 10 Hamilton (2024012714033572800_jbmr4480-bib-0039) 1983; 43 Fuller (2024012714033572800_jbmr4480-bib-0016) 1998; 188 Breese (2024012714033572800_jbmr4480-bib-0044) 2013; 29 Bonetto (2024012714033572800_jbmr4480-bib-0037) 2016; 30 Edgar (2024012714033572800_jbmr4480-bib-0048) 2002; 30 Torres (2024012714033572800_jbmr4480-bib-0053) 2013; 129 Guntur (2024012714033572800_jbmr4480-bib-0008) 2012; 18 Santini (2024012714033572800_jbmr4480-bib-0020) 2011; 226 Agarwala (2024012714033572800_jbmr4480-bib-0062) 2019; 43 Theoleyre (2024012714033572800_jbmr4480-bib-0022) 2004; 15 Huot (2024012714033572800_jbmr4480-bib-0042) 2020; 11 Kanematsu (2024012714033572800_jbmr4480-bib-0071) 2000; 15 Domcke (2024012714033572800_jbmr4480-bib-0035) 2013; 4 Lipton (2024012714033572800_jbmr4480-bib-0079) 2012; 6 Jones (2024012714033572800_jbmr4480-bib-0019) 2006; 440 Dufresne (2024012714033572800_jbmr4480-bib-0025) 2018; 6 Zhang (2024012714033572800_jbmr4480-bib-0021) 2018; 51 Plotkin (2024012714033572800_jbmr4480-bib-0068) 1999; 104 Zhang (2024012714033572800_jbmr4480-bib-0077) 2020; 8 Lee (2024012714033572800_jbmr4480-bib-0057) 2020; 63 Hamoudi (2024012714033572800_jbmr4480-bib-0026) 2019; 28 Amin (2024012714033572800_jbmr4480-bib-0030) 2017; 67 Meeske (2024012714033572800_jbmr4480-bib-0006) 2007; 16 Ewels (2024012714033572800_jbmr4480-bib-0046) 2016; 32 Fearon (2024012714033572800_jbmr4480-bib-0007) 2011; 12 Mourtzakis (2024012714033572800_jbmr4480-bib-0049) 2008; 33 Chen (2024012714033572800_jbmr4480-bib-0040) 2014; 28 Mitra (2024012714033572800_jbmr4480-bib-0036) 2015; 138 Liao (2024012714033572800_jbmr4480-bib-0045) 2014; 30 Leibbrandt (2024012714033572800_jbmr4480-bib-0023) 2008; 1143 Pin (2024012714033572800_jbmr4480-bib-0066) 2021; 520 Robinson (2024012714033572800_jbmr4480-bib-0047) 2010; 26 Luan (2024012714033572800_jbmr4480-bib-0024) 2012; 189 Seyberth (2024012714033572800_jbmr4480-bib-0059) 1975; 293 Chandrashekar (2024012714033572800_jbmr4480-bib-0082) 2017; 19 Plotkin (2024012714033572800_jbmr4480-bib-0067) 2015; 290 von Moos (2024012714033572800_jbmr4480-bib-0064) 2019; 76 Sherwin (2024012714033572800_jbmr4480-bib-0060) 1983; 43 Huang (2024012714033572800_jbmr4480-bib-0004) 2020; 11 Anglesio (2024012714033572800_jbmr4480-bib-0081) 2013; 8 Gadducci (2024012714033572800_jbmr4480-bib-0003) 2001; 21 Waning (2024012714033572800_jbmr4480-bib-0010) 2015; 21 Fearon (2024012714033572800_jbmr4480-bib-0032) 2006; 83 Siegel (2024012714033572800_jbmr4480-bib-0001) 2020; 70 Hayes (2024012714033572800_jbmr4480-bib-0005) 2005; 94 Roby (2024012714033572800_jbmr4480-bib-0038) 2000; 21 Silva de Paula (2024012714033572800_jbmr4480-bib-0034) 2018; 28 Barreto (2024012714033572800_jbmr4480-bib-0015) 2017; 7 Huot (2024012714033572800_jbmr4480-bib-0052) 2020; 5 Rutten (2024012714033572800_jbmr4480-bib-0054) 2017; 43 Hamoudi (2024012714033572800_jbmr4480-bib-0074) 2020; 29 Essex (2024012714033572800_jbmr4480-bib-0014) 2019; 10 Berruti (2024012714033572800_jbmr4480-bib-0055) 2002; 167 Kostenuik (2024012714033572800_jbmr4480-bib-0076) 2009; 24 McClung (2024012714033572800_jbmr4480-bib-0078) 2006; 4 Pin (2024012714033572800_jbmr4480-bib-0051) 2019; 10 Borsheim (2024012714033572800_jbmr4480-bib-0065) 2014; 29 Li (2024012714033572800_jbmr4480-bib-0028) 2020; 35 O'Carrigan (2024012714033572800_jbmr4480-bib-0063) 2017; 10 Wright (2024012714033572800_jbmr4480-bib-0011) 2017; 8 Severinsen (2024012714033572800_jbmr4480-bib-0009) 2020; 41 35067972 - J Bone Miner Res. 2022 Mar;37(3):379-380 |
| References_xml | – volume: 27 start-page: 793 issue: 6 year: 2008 end-page: 799 article-title: Cachexia: a new definition publication-title: Clin Nutr. – volume: 218 issue: 6 year: 2021 article-title: Tumor‐derived IL‐6 and trans‐signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia publication-title: J Exp Med – volume: 94 start-page: 1 issue: 1 year: 2005 end-page: 10 article-title: Objective and subjective upper body function six months following diagnosis of breast cancer publication-title: Breast Cancer Res Treat. – volume: 43 start-page: 717 issue: 4 year: 2017 end-page: 724 article-title: The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery publication-title: Eur J Surg Oncol. – volume: 11 start-page: 534 issue: 2 year: 2020 end-page: 546 article-title: Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced‐stage ovarian cancer publication-title: J Cachexia Sarcopenia Muscle. – volume: 16 start-page: 947 issue: 6 year: 2007 end-page: 960 article-title: Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL Study report publication-title: Qual Life Res. – volume: 1143 start-page: 123 year: 2008 end-page: 150 article-title: RANK/RANKL: regulators of immune responses and bone physiology publication-title: Ann N Y Acad Sci. – volume: 5 start-page: 649 issue: 6 year: 1982 end-page: 655 article-title: Toxicity and response criteria of the Eastern Cooperative Oncology Group publication-title: Am J Clin Oncol. – volume: 10 year: 2017 article-title: Bisphosphonates and other bone agents for breast cancer publication-title: Cochrane Database Syst Rev – volume: 167 start-page: 2361 issue: 6 year: 2002 end-page: 2367 article-title: Changes in bone mineral density, lean body mass and fat content as measured by dual energy X‐ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy publication-title: J Urol. – volume: 21 start-page: 1262 issue: 11 year: 2015 end-page: 1271 article-title: Excess TGF‐beta mediates muscle weakness associated with bone metastases in mice publication-title: Nat Med. – volume: 7 start-page: 14470 issue: 1 year: 2017 article-title: ACVR2B/Fc counteracts chemotherapy‐induced loss of muscle and bone mass publication-title: Sci Rep – volume: 4 start-page: 28 issue: 1 year: 2006 end-page: 33 article-title: Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies publication-title: Curr Osteoporos Rep. – volume: 138 start-page: 372 issue: 2 year: 2015 end-page: 377 article-title: In vivo tumor growth of high‐grade serous ovarian cancer cell lines publication-title: Gynecol Oncol. – volume: 129 start-page: 3214 issue: 8 year: 2019 end-page: 3223 article-title: RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass publication-title: J Clin Invest. – volume: 8 start-page: 325 year: 2020 article-title: Pros and cons of denosumab treatment for osteoporosis and implication for RANKL aptamer therapy publication-title: Front Cell Dev Biol. – volume: 43 start-page: 314 issue: 3 year: 2019 end-page: 320 article-title: Single dose therapy of zoledronic acid for the treatment of transient osteoporosis of hip publication-title: Ann Rehabil Med. – volume: 8 issue: 9 year: 2013 article-title: Type‐specific cell line models for type‐specific ovarian cancer research publication-title: PLoS One. – volume: 83 start-page: 1345 issue: 6 year: 2006 end-page: 1350 article-title: Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis publication-title: Am J Clin Nutr. – volume: 76 start-page: 57 year: 2019 end-page: 67 article-title: Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody publication-title: Cancer Treat Rev. – volume: 28 start-page: 412 issue: 2 year: 2018 end-page: 420 article-title: Sarcopenia and skeletal muscle quality as predictors of postoperative complication and early mortality in gynecologic cancer publication-title: Int J Gynecol Cancer – volume: 6 start-page: 287 year: 2012 end-page: 303 article-title: Treatment‐induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab publication-title: Clin Med Insights Oncol. – volume: 27 start-page: 223 issue: 2 year: 2017 end-page: 232 article-title: Sarcopenia in advanced serous ovarian cancer publication-title: Int J Gynecol Cancer. – volume: 10 start-page: 809 year: 2019 article-title: Bisphosphonate treatment ameliorates chemotherapy‐induced bone and muscle abnormalities in young mice publication-title: Front Endocrinol (Lausanne). – volume: 29 start-page: 15 issue: 1 year: 2013 end-page: 21 article-title: STAR: ultrafast universal RNA‐seq aligner publication-title: Bioinformatics – volume: 10 issue: 9 year: 2015 article-title: Osteocytes, not osteoblasts or lining cells, are the main source of the RANKL required for osteoclast formation in remodeling bone publication-title: PLoS One. – volume: 29 start-page: 494 issue: 4 year: 2013 end-page: 496 article-title: NGSUtils: a software suite for analyzing and manipulating next‐generation sequencing datasets publication-title: Bioinformatics. – volume: 36 issue: 4 year: 2016 article-title: RANK‐RANKL signalling in cancer publication-title: Biosci Rep – volume: 29 start-page: 483 issue: 3 year: 2020 end-page: 494 article-title: Muscle weakness and selective muscle atrophy in osteoprotegerin‐deficient mice publication-title: Hum Mol Genet. – volume: 1830 start-page: 2770 issue: 3 year: 2013 end-page: 2778 article-title: Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency? publication-title: Biochim Biophys Acta. – volume: 310 start-page: C663 issue: 8 year: 2016 end-page: C672 article-title: Muscle RANK is a key regulator of Ca2+ storage, SERCA activity, and function of fast‐twitch skeletal muscles publication-title: Am J Physiol Cell Physiol – volume: 188 start-page: 997 issue: 5 year: 1998 end-page: 1001 article-title: TRANCE is necessary and sufficient for osteoblast‐mediated activation of bone resorption in osteoclasts publication-title: J Exp Med – volume: 50 start-page: 104 issue: 1 year: 2012 end-page: 110 article-title: Osteocyte apoptosis regulates osteoclast precursor adhesion via osteocytic IL‐6 secretion and endothelial ICAM‐1 expression publication-title: Bone. – volume: 276 start-page: 20659 issue: 23 year: 2001 end-page: 20672 article-title: Receptor activator of NF‐kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis publication-title: J Biol Chem. – volume: 18 start-page: 758 issue: 5 year: 2012 end-page: 762 article-title: Bone as an endocrine organ publication-title: Endocr Pract. – volume: 11 start-page: 1779 issue: 6 year: 2020 end-page: 1798 article-title: ACVR2B antagonism as a countermeasure to multi‐organ perturbations in metastatic colorectal cancer cachexia publication-title: J Cachexia Sarcopenia Muscle. – volume: 9 start-page: 685 issue: 4 year: 2018 end-page: 700 article-title: Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia publication-title: J Cachexia Sarcopenia Muscle. – volume: 21 start-page: 2941 issue: 4B year: 2001 end-page: 2947 article-title: Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management publication-title: Anticancer Res. – volume: 43 start-page: 403 issue: 1 year: 1983 end-page: 407 article-title: High‐molecular‐weight transforming growth factor activity in the urine of patients with disseminated cancer publication-title: Cancer Res. – volume: 63 start-page: 470 issue: 4 year: 2020 end-page: 479 article-title: Effect of gynecological cancer and its treatment on bone mineral density and the risk of osteoporosis and osteoporotic fracture publication-title: Obstet Gynecol Sci. – volume: 51 start-page: e6265 issue: 3 year: 2018 article-title: Rankl expression predicts poor prognosis in gastric cancer patients: results from a retrospective and single‐center analysis publication-title: Braz J Med Biol Res – volume: 32 start-page: 3047 issue: 19 year: 2016 end-page: 3048 article-title: MultiQC: summarize analysis results for multiple tools and samples in a single report publication-title: Bioinformatics. – volume: 24 start-page: 182 issue: 2 year: 2009 end-page: 195 article-title: Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock‐in mice that express chimeric (murine/human) RANKL publication-title: J Bone Miner Res. – volume: 30 start-page: 207 issue: 1 year: 2002 end-page: 210 article-title: Gene Expression Omnibus: NCBI gene expression and hybridization array data repository publication-title: Nucleic Acids Res. – volume: 21 start-page: 585 issue: 4 year: 2000 end-page: 591 article-title: Development of a syngeneic mouse model for events related to ovarian cancer publication-title: Carcinogenesis. – volume: 15 start-page: 1321 issue: 7 year: 2000 end-page: 1329 article-title: Prostaglandin E2 induces expression of receptor activator of nuclear factor‐kappa B ligand/osteoprotegrin ligand on pre‐B cells: implications for accelerated osteoclastogenesis in estrogen deficiency publication-title: J Bone Miner Res. – volume: 520 start-page: 80 year: 2021 end-page: 90 article-title: Non‐bone metastatic cancers promote osteocyte‐induced bone destruction publication-title: Cancer Lett. – volume: 10 start-page: 543 year: 2019 article-title: Molecular mechanisms responsible for the rescue effects of pamidronate on muscle atrophy in pediatric burn patients publication-title: Front Endocrinol (Lausanne). – volume: 29 start-page: 1369 issue: 6 year: 2014 end-page: 1372 article-title: Pamidronate attenuates muscle loss after pediatric burn injury publication-title: J Bone Miner Res. – volume: 189 start-page: 245 issue: 1 year: 2012 end-page: 252 article-title: Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin publication-title: J Immunol. – volume: 4 start-page: 2126 year: 2013 article-title: Evaluating cell lines as tumour models by comparison of genomic profiles publication-title: Nat Commun. – volume: 30 start-page: 923 issue: 7 year: 2014 end-page: 930 article-title: featureCounts: an efficient general purpose program for assigning sequence reads to genomic features publication-title: Bioinformatics. – volume: 5 issue: 9 year: 2020 article-title: Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia publication-title: JCI Insight. – volume: 29 start-page: 1158 issue: 5 year: 2014 end-page: 1169 article-title: Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice publication-title: J Bone Miner Res. – volume: 129 start-page: 548 issue: 3 year: 2013 end-page: 553 article-title: Nutritional status, CT body composition measures and survival in ovarian cancer publication-title: Gynecol Oncol. – volume: 191 start-page: 1395 issue: 7 year: 2010 end-page: 1411 article-title: Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice publication-title: J Cell Biol. – volume: 290 start-page: 18934 issue: 31 year: 2015 end-page: 18942 article-title: Inhibition of osteocyte apoptosis prevents the increase in osteocytic receptor activator of nuclear factor kappaB ligand (RANKL) but does not stop bone resorption or the loss of bone induced by unloading publication-title: J Biol Chem – volume: 43 start-page: 5379 issue: 11 year: 1983 end-page: 5389 article-title: Characterization of a human ovarian carcinoma cell line (NIH:OVCAR‐3) with androgen and estrogen receptors publication-title: Cancer Res. – volume: 8 start-page: 8406 issue: 5 year: 2017 end-page: 8419 article-title: Aromatase inhibitor‐induced bone loss increases the progression of estrogen receptor‐negative breast cancer in bone and exacerbates muscle weakness in vivo publication-title: Oncotarget. – volume: 12 start-page: 489 issue: 5 year: 2011 end-page: 495 article-title: Definition and classification of cancer cachexia: an international consensus publication-title: Lancet Oncol. – volume: 7 start-page: 679 year: 2016 article-title: Differential bone loss in mouse models of colon cancer cachexia publication-title: Front Physiol. – volume: 35 start-page: 1535 issue: 8 year: 2020 end-page: 1548 article-title: TNF receptor‐associated factor 6 mediates TNFalpha‐induced skeletal muscle atrophy in mice during aging publication-title: J Bone Miner Res. – volume: 54 start-page: 607 issue: 4 year: 1999 end-page: 611 article-title: Androgen deprivation therapy for prostate cancer results in significant loss of bone density publication-title: Urology. – volume: 11 issue: 6 year: 2019 article-title: Clinical impact of RANK signalling in ovarian cancer publication-title: Cancers – volume: 293 start-page: 1278 issue: 25 year: 1975 end-page: 1283 article-title: Prostaglandins as mediators of hypercalcemia associated with certain types of cancer publication-title: N Engl J Med – volume: 67 start-page: 93 issue: 2 year: 2017 end-page: 99 article-title: The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population‐based to a more "personalized" approach to cancer staging publication-title: CA Cancer J Clin. – volume: 6 start-page: 31 issue: 1 year: 2018 article-title: Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full‐length OPG‐fc in mitigating muscular dystrophy publication-title: Acta Neuropathol Commun – volume: 104 start-page: 1363 issue: 10 year: 1999 end-page: 1374 article-title: Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin publication-title: J Clin Invest. – volume: 30 start-page: 54893 issue: 117 year: 2016 article-title: The Colon‐26 carcinoma tumor‐bearing mouse as a model for the study of cancer cachexia publication-title: J Vis Exp – volume: 41 start-page: 594 issue: 4 year: 2020 end-page: 609 article-title: Muscle‐organ crosstalk: the emerging roles of myokines publication-title: Endocr Rev – volume: 28 start-page: 1711 issue: 4 year: 2014 end-page: 1723 article-title: Elevated expression of activins promotes muscle wasting and cachexia publication-title: FASEB J. – volume: 440 start-page: 692 issue: 7084 year: 2006 end-page: 696 article-title: Regulation of cancer cell migration and bone metastasis by RANKL publication-title: Nature. – volume: 32 start-page: 422 issue: 10 year: 2002 end-page: 424 article-title: Prospective study of decreased bone mineral density in patients with cervical cancer without bone metastases: a preliminary report publication-title: Jpn J Clin Oncol. – volume: 70 start-page: 7 issue: 1 year: 2020 end-page: 30 article-title: Cancer statistics, 2020 publication-title: CA Cancer J Clin. – volume: 237 start-page: 893 issue: 4817 year: 1987 end-page: 896 article-title: A parathyroid hormone‐related protein implicated in malignant hypercalcemia: cloning and expression publication-title: Science – volume: 11 start-page: 3482 issue: 24 year: 1997 end-page: 3496 article-title: Requirement for NF‐kappaB in osteoclast and B‐cell development publication-title: Genes Dev – volume: 226 start-page: 780 issue: 3 year: 2011 end-page: 784 article-title: Expression pattern of receptor activator of NFkappaB (RANK) in a series of primary solid tumors and related bone metastases publication-title: J Cell Physiol. – volume: 33 start-page: 997 issue: 5 year: 2008 end-page: 1006 article-title: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care publication-title: Appl Physiol Nutr Metab. – volume: 28 start-page: 3101 issue: 18 year: 2019 end-page: 3112 article-title: An anti‐RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice publication-title: Hum Mol Genet – volume: 15 start-page: 457 issue: 6 year: 2004 end-page: 475 article-title: The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling publication-title: Cytokine Growth Factor Rev. – volume: 26 start-page: 139 issue: 1 year: 2010 end-page: 140 article-title: edgeR: a bioconductor package for differential expression analysis of digital gene expression data publication-title: Bioinformatics. – volume: 19 start-page: 649 issue: 8 year: 2017 end-page: 658 article-title: UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses publication-title: Neoplasia. – volume: 10 start-page: 809 year: 2019 ident: 2024012714033572800_jbmr4480-bib-0014 article-title: Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice publication-title: Front Endocrinol (Lausanne). doi: 10.3389/fendo.2019.00809 – volume: 11 start-page: 1779 issue: 6 year: 2020 ident: 2024012714033572800_jbmr4480-bib-0042 article-title: ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia publication-title: J Cachexia Sarcopenia Muscle. doi: 10.1002/jcsm.12642 – volume: 29 start-page: 494 issue: 4 year: 2013 ident: 2024012714033572800_jbmr4480-bib-0044 article-title: NGSUtils: a software suite for analyzing and manipulating next-generation sequencing datasets publication-title: Bioinformatics. doi: 10.1093/bioinformatics/bts731 – volume: 11 start-page: 534 issue: 2 year: 2020 ident: 2024012714033572800_jbmr4480-bib-0004 article-title: Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer publication-title: J Cachexia Sarcopenia Muscle. doi: 10.1002/jcsm.12524 – volume: 70 start-page: 7 issue: 1 year: 2020 ident: 2024012714033572800_jbmr4480-bib-0001 article-title: Cancer statistics, 2020 publication-title: CA Cancer J Clin. doi: 10.3322/caac.21590 – volume: 27 start-page: 223 issue: 2 year: 2017 ident: 2024012714033572800_jbmr4480-bib-0002 article-title: Sarcopenia in advanced serous ovarian cancer publication-title: Int J Gynecol Cancer. doi: 10.1097/IGC.0000000000000867 – volume: 7 start-page: 14470 issue: 1 year: 2017 ident: 2024012714033572800_jbmr4480-bib-0015 article-title: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass publication-title: Sci Rep doi: 10.1038/s41598-017-15040-1 – volume: 218 start-page: e20190450 issue: 6 year: 2021 ident: 2024012714033572800_jbmr4480-bib-0069 article-title: Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia publication-title: J Exp Med doi: 10.1084/jem.20190450 – volume: 9 start-page: 685 issue: 4 year: 2018 ident: 2024012714033572800_jbmr4480-bib-0012 article-title: Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia publication-title: J Cachexia Sarcopenia Muscle. doi: 10.1002/jcsm.12311 – volume: 15 start-page: 457 issue: 6 year: 2004 ident: 2024012714033572800_jbmr4480-bib-0022 article-title: The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling publication-title: Cytokine Growth Factor Rev. doi: 10.1016/j.cytogfr.2004.06.004 – volume: 35 start-page: 1535 issue: 8 year: 2020 ident: 2024012714033572800_jbmr4480-bib-0028 article-title: TNF receptor-associated factor 6 mediates TNFalpha-induced skeletal muscle atrophy in mice during aging publication-title: J Bone Miner Res. doi: 10.1002/jbmr.4021 – volume: 11 start-page: 3482 issue: 24 year: 1997 ident: 2024012714033572800_jbmr4480-bib-0080 article-title: Requirement for NF-kappaB in osteoclast and B-cell development publication-title: Genes Dev doi: 10.1101/gad.11.24.3482 – volume: 21 start-page: 585 issue: 4 year: 2000 ident: 2024012714033572800_jbmr4480-bib-0038 article-title: Development of a syngeneic mouse model for events related to ovarian cancer publication-title: Carcinogenesis. doi: 10.1093/carcin/21.4.585 – volume: 21 start-page: 1262 issue: 11 year: 2015 ident: 2024012714033572800_jbmr4480-bib-0010 article-title: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice publication-title: Nat Med. doi: 10.1038/nm.3961 – volume: 43 start-page: 5379 issue: 11 year: 1983 ident: 2024012714033572800_jbmr4480-bib-0039 article-title: Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors publication-title: Cancer Res. – volume: 310 start-page: C663 issue: 8 year: 2016 ident: 2024012714033572800_jbmr4480-bib-0017 article-title: Muscle RANK is a key regulator of Ca2+ storage, SERCA activity, and function of fast-twitch skeletal muscles publication-title: Am J Physiol Cell Physiol doi: 10.1152/ajpcell.00285.2015 – volume: 41 start-page: 594 issue: 4 year: 2020 ident: 2024012714033572800_jbmr4480-bib-0009 article-title: Muscle-organ crosstalk: the emerging roles of myokines publication-title: Endocr Rev doi: 10.1210/endrev/bnaa016 – volume: 29 start-page: 483 issue: 3 year: 2020 ident: 2024012714033572800_jbmr4480-bib-0074 article-title: Muscle weakness and selective muscle atrophy in osteoprotegerin-deficient mice publication-title: Hum Mol Genet. doi: 10.1093/hmg/ddz312 – volume: 4 start-page: 28 issue: 1 year: 2006 ident: 2024012714033572800_jbmr4480-bib-0078 article-title: Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies publication-title: Curr Osteoporos Rep. doi: 10.1007/s11914-006-0012-7 – volume: 28 start-page: 3101 issue: 18 year: 2019 ident: 2024012714033572800_jbmr4480-bib-0026 article-title: An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice publication-title: Hum Mol Genet doi: 10.1093/hmg/ddz124 – volume: 27 start-page: 793 issue: 6 year: 2008 ident: 2024012714033572800_jbmr4480-bib-0033 article-title: Cachexia: a new definition publication-title: Clin Nutr. doi: 10.1016/j.clnu.2008.06.013 – volume: 10 start-page: CD003474 year: 2017 ident: 2024012714033572800_jbmr4480-bib-0063 article-title: Bisphosphonates and other bone agents for breast cancer publication-title: Cochrane Database Syst Rev – volume: 276 start-page: 20659 issue: 23 year: 2001 ident: 2024012714033572800_jbmr4480-bib-0072 article-title: Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis publication-title: J Biol Chem. doi: 10.1074/jbc.M010153200 – volume: 129 start-page: 548 issue: 3 year: 2013 ident: 2024012714033572800_jbmr4480-bib-0053 article-title: Nutritional status, CT body composition measures and survival in ovarian cancer publication-title: Gynecol Oncol. doi: 10.1016/j.ygyno.2013.03.003 – volume: 32 start-page: 422 issue: 10 year: 2002 ident: 2024012714033572800_jbmr4480-bib-0058 article-title: Prospective study of decreased bone mineral density in patients with cervical cancer without bone metastases: a preliminary report publication-title: Jpn J Clin Oncol. doi: 10.1093/jjco/hyf082 – volume: 33 start-page: 997 issue: 5 year: 2008 ident: 2024012714033572800_jbmr4480-bib-0049 article-title: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care publication-title: Appl Physiol Nutr Metab. doi: 10.1139/H08-075 – volume: 21 start-page: 2941 issue: 4B year: 2001 ident: 2024012714033572800_jbmr4480-bib-0003 article-title: Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management publication-title: Anticancer Res. – volume: 6 start-page: 287 year: 2012 ident: 2024012714033572800_jbmr4480-bib-0079 article-title: Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab publication-title: Clin Med Insights Oncol. doi: 10.4137/CMO.S8511 – volume: 10 start-page: e0138189 issue: 9 year: 2015 ident: 2024012714033572800_jbmr4480-bib-0070 article-title: Osteocytes, not osteoblasts or lining cells, are the main source of the RANKL required for osteoclast formation in remodeling bone publication-title: PLoS One. doi: 10.1371/journal.pone.0138189 – volume: 5 start-page: e136687 issue: 9 year: 2020 ident: 2024012714033572800_jbmr4480-bib-0052 article-title: Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia publication-title: JCI Insight. doi: 10.1172/jci.insight.136687 – volume: 4 start-page: 2126 year: 2013 ident: 2024012714033572800_jbmr4480-bib-0035 article-title: Evaluating cell lines as tumour models by comparison of genomic profiles publication-title: Nat Commun. doi: 10.1038/ncomms3126 – volume: 32 start-page: 3047 issue: 19 year: 2016 ident: 2024012714033572800_jbmr4480-bib-0046 article-title: MultiQC: summarize analysis results for multiple tools and samples in a single report publication-title: Bioinformatics. doi: 10.1093/bioinformatics/btw354 – volume: 8 start-page: 325 year: 2020 ident: 2024012714033572800_jbmr4480-bib-0077 article-title: Pros and cons of denosumab treatment for osteoporosis and implication for RANKL aptamer therapy publication-title: Front Cell Dev Biol. doi: 10.3389/fcell.2020.00325 – volume: 36 start-page: e00366 issue: 4 year: 2016 ident: 2024012714033572800_jbmr4480-bib-0073 article-title: RANK-RANKL signalling in cancer publication-title: Biosci Rep doi: 10.1042/BSR20160150 – volume: 29 start-page: 1158 issue: 5 year: 2014 ident: 2024012714033572800_jbmr4480-bib-0075 article-title: Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice publication-title: J Bone Miner Res. doi: 10.1002/jbmr.2112 – volume: 7 start-page: 679 year: 2016 ident: 2024012714033572800_jbmr4480-bib-0013 article-title: Differential bone loss in mouse models of colon cancer cachexia publication-title: Front Physiol. – volume: 12 start-page: 489 issue: 5 year: 2011 ident: 2024012714033572800_jbmr4480-bib-0007 article-title: Definition and classification of cancer cachexia: an international consensus publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(10)70218-7 – volume: 1830 start-page: 2770 issue: 3 year: 2013 ident: 2024012714033572800_jbmr4480-bib-0041 article-title: Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency? publication-title: Biochim Biophys Acta. doi: 10.1016/j.bbagen.2012.11.009 – volume: 94 start-page: 1 issue: 1 year: 2005 ident: 2024012714033572800_jbmr4480-bib-0005 article-title: Objective and subjective upper body function six months following diagnosis of breast cancer publication-title: Breast Cancer Res Treat. doi: 10.1007/s10549-005-5991-z – volume: 43 start-page: 717 issue: 4 year: 2017 ident: 2024012714033572800_jbmr4480-bib-0054 article-title: The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery publication-title: Eur J Surg Oncol. doi: 10.1016/j.ejso.2016.12.016 – volume: 63 start-page: 470 issue: 4 year: 2020 ident: 2024012714033572800_jbmr4480-bib-0057 article-title: Effect of gynecological cancer and its treatment on bone mineral density and the risk of osteoporosis and osteoporotic fracture publication-title: Obstet Gynecol Sci. doi: 10.5468/ogs.20012 – volume: 19 start-page: 649 issue: 8 year: 2017 ident: 2024012714033572800_jbmr4480-bib-0082 article-title: UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses publication-title: Neoplasia. doi: 10.1016/j.neo.2017.05.002 – volume: 16 start-page: 947 issue: 6 year: 2007 ident: 2024012714033572800_jbmr4480-bib-0006 article-title: Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL Study report publication-title: Qual Life Res. doi: 10.1007/s11136-007-9215-3 – volume: 191 start-page: 1395 issue: 7 year: 2010 ident: 2024012714033572800_jbmr4480-bib-0029 article-title: Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice publication-title: J Cell Biol. doi: 10.1083/jcb.201006098 – volume: 6 start-page: 31 issue: 1 year: 2018 ident: 2024012714033572800_jbmr4480-bib-0025 article-title: Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy publication-title: Acta Neuropathol Commun doi: 10.1186/s40478-018-0533-1 – volume: 290 start-page: 18934 issue: 31 year: 2015 ident: 2024012714033572800_jbmr4480-bib-0067 article-title: Inhibition of osteocyte apoptosis prevents the increase in osteocytic receptor activator of nuclear factor kappaB ligand (RANKL) but does not stop bone resorption or the loss of bone induced by unloading publication-title: J Biol Chem doi: 10.1074/jbc.M115.642090 – volume: 43 start-page: 314 issue: 3 year: 2019 ident: 2024012714033572800_jbmr4480-bib-0062 article-title: Single dose therapy of zoledronic acid for the treatment of transient osteoporosis of hip publication-title: Ann Rehabil Med. doi: 10.5535/arm.2019.43.3.314 – volume: 5 start-page: 649 issue: 6 year: 1982 ident: 2024012714033572800_jbmr4480-bib-0031 article-title: Toxicity and response criteria of the Eastern Cooperative Oncology Group publication-title: Am J Clin Oncol. doi: 10.1097/00000421-198212000-00014 – volume: 293 start-page: 1278 issue: 25 year: 1975 ident: 2024012714033572800_jbmr4480-bib-0059 article-title: Prostaglandins as mediators of hypercalcemia associated with certain types of cancer publication-title: N Engl J Med doi: 10.1056/NEJM197512182932502 – volume: 167 start-page: 2361 issue: 6 year: 2002 ident: 2024012714033572800_jbmr4480-bib-0055 article-title: Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy publication-title: J Urol. doi: 10.1016/S0022-5347(05)64985-3 – volume: 67 start-page: 93 issue: 2 year: 2017 ident: 2024012714033572800_jbmr4480-bib-0030 article-title: The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging publication-title: CA Cancer J Clin. doi: 10.3322/caac.21388 – volume: 83 start-page: 1345 issue: 6 year: 2006 ident: 2024012714033572800_jbmr4480-bib-0032 article-title: Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis publication-title: Am J Clin Nutr. doi: 10.1093/ajcn/83.6.1345 – volume: 28 start-page: 1711 issue: 4 year: 2014 ident: 2024012714033572800_jbmr4480-bib-0040 article-title: Elevated expression of activins promotes muscle wasting and cachexia publication-title: FASEB J. doi: 10.1096/fj.13-245894 – volume: 8 start-page: 8406 issue: 5 year: 2017 ident: 2024012714033572800_jbmr4480-bib-0011 article-title: Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo publication-title: Oncotarget. doi: 10.18632/oncotarget.14139 – volume: 51 start-page: e6265 issue: 3 year: 2018 ident: 2024012714033572800_jbmr4480-bib-0021 article-title: Rankl expression predicts poor prognosis in gastric cancer patients: results from a retrospective and single-center analysis publication-title: Braz J Med Biol Res doi: 10.1590/1414-431x20176265 – volume: 520 start-page: 80 year: 2021 ident: 2024012714033572800_jbmr4480-bib-0066 article-title: Non-bone metastatic cancers promote osteocyte-induced bone destruction publication-title: Cancer Lett. doi: 10.1016/j.canlet.2021.06.030 – volume: 8 start-page: e72162 issue: 9 year: 2013 ident: 2024012714033572800_jbmr4480-bib-0081 article-title: Type-specific cell line models for type-specific ovarian cancer research publication-title: PLoS One. doi: 10.1371/journal.pone.0072162 – volume: 50 start-page: 104 issue: 1 year: 2012 ident: 2024012714033572800_jbmr4480-bib-0050 article-title: Osteocyte apoptosis regulates osteoclast precursor adhesion via osteocytic IL-6 secretion and endothelial ICAM-1 expression publication-title: Bone. doi: 10.1016/j.bone.2011.09.052 – volume: 226 start-page: 780 issue: 3 year: 2011 ident: 2024012714033572800_jbmr4480-bib-0020 article-title: Expression pattern of receptor activator of NFkappaB (RANK) in a series of primary solid tumors and related bone metastases publication-title: J Cell Physiol. doi: 10.1002/jcp.22402 – volume: 18 start-page: 758 issue: 5 year: 2012 ident: 2024012714033572800_jbmr4480-bib-0008 article-title: Bone as an endocrine organ publication-title: Endocr Pract. doi: 10.4158/EP12141.RA – volume: 189 start-page: 245 issue: 1 year: 2012 ident: 2024012714033572800_jbmr4480-bib-0024 article-title: Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin publication-title: J Immunol. doi: 10.4049/jimmunol.1103387 – volume: 76 start-page: 57 year: 2019 ident: 2024012714033572800_jbmr4480-bib-0064 article-title: Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody publication-title: Cancer Treat Rev. doi: 10.1016/j.ctrv.2019.05.003 – volume: 29 start-page: 1369 issue: 6 year: 2014 ident: 2024012714033572800_jbmr4480-bib-0065 article-title: Pamidronate attenuates muscle loss after pediatric burn injury publication-title: J Bone Miner Res. doi: 10.1002/jbmr.2162 – volume: 15 start-page: 1321 issue: 7 year: 2000 ident: 2024012714033572800_jbmr4480-bib-0071 article-title: Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency publication-title: J Bone Miner Res. doi: 10.1359/jbmr.2000.15.7.1321 – volume: 43 start-page: 403 issue: 1 year: 1983 ident: 2024012714033572800_jbmr4480-bib-0060 article-title: High-molecular-weight transforming growth factor activity in the urine of patients with disseminated cancer publication-title: Cancer Res. – volume: 30 start-page: 923 issue: 7 year: 2014 ident: 2024012714033572800_jbmr4480-bib-0045 article-title: featureCounts: an efficient general purpose program for assigning sequence reads to genomic features publication-title: Bioinformatics. doi: 10.1093/bioinformatics/btt656 – volume: 54 start-page: 607 issue: 4 year: 1999 ident: 2024012714033572800_jbmr4480-bib-0056 article-title: Androgen deprivation therapy for prostate cancer results in significant loss of bone density publication-title: Urology. doi: 10.1016/S0090-4295(99)00301-5 – volume: 24 start-page: 182 issue: 2 year: 2009 ident: 2024012714033572800_jbmr4480-bib-0076 article-title: Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL publication-title: J Bone Miner Res. doi: 10.1359/jbmr.081112 – volume: 30 start-page: 207 issue: 1 year: 2002 ident: 2024012714033572800_jbmr4480-bib-0048 article-title: Gene Expression Omnibus: NCBI gene expression and hybridization array data repository publication-title: Nucleic Acids Res. doi: 10.1093/nar/30.1.207 – volume: 129 start-page: 3214 issue: 8 year: 2019 ident: 2024012714033572800_jbmr4480-bib-0027 article-title: RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass publication-title: J Clin Invest. doi: 10.1172/JCI125915 – volume: 10 start-page: 543 year: 2019 ident: 2024012714033572800_jbmr4480-bib-0051 article-title: Molecular mechanisms responsible for the rescue effects of pamidronate on muscle atrophy in pediatric burn patients publication-title: Front Endocrinol (Lausanne). doi: 10.3389/fendo.2019.00543 – volume: 440 start-page: 692 issue: 7084 year: 2006 ident: 2024012714033572800_jbmr4480-bib-0019 article-title: Regulation of cancer cell migration and bone metastasis by RANKL publication-title: Nature. doi: 10.1038/nature04524 – volume: 237 start-page: 893 issue: 4817 year: 1987 ident: 2024012714033572800_jbmr4480-bib-0061 article-title: A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression publication-title: Science doi: 10.1126/science.3616618 – volume: 26 start-page: 139 issue: 1 year: 2010 ident: 2024012714033572800_jbmr4480-bib-0047 article-title: edgeR: a bioconductor package for differential expression analysis of digital gene expression data publication-title: Bioinformatics. doi: 10.1093/bioinformatics/btp616 – volume: 30 start-page: 54893 issue: 117 year: 2016 ident: 2024012714033572800_jbmr4480-bib-0037 article-title: The Colon-26 carcinoma tumor-bearing mouse as a model for the study of cancer cachexia publication-title: J Vis Exp – volume: 104 start-page: 1363 issue: 10 year: 1999 ident: 2024012714033572800_jbmr4480-bib-0068 article-title: Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin publication-title: J Clin Invest. doi: 10.1172/JCI6800 – volume: 138 start-page: 372 issue: 2 year: 2015 ident: 2024012714033572800_jbmr4480-bib-0036 article-title: In vivo tumor growth of high-grade serous ovarian cancer cell lines publication-title: Gynecol Oncol. doi: 10.1016/j.ygyno.2015.05.040 – volume: 188 start-page: 997 issue: 5 year: 1998 ident: 2024012714033572800_jbmr4480-bib-0016 article-title: TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts publication-title: J Exp Med doi: 10.1084/jem.188.5.997 – volume: 1143 start-page: 123 year: 2008 ident: 2024012714033572800_jbmr4480-bib-0023 article-title: RANK/RANKL: regulators of immune responses and bone physiology publication-title: Ann N Y Acad Sci. doi: 10.1196/annals.1443.016 – volume: 11 start-page: 791 issue: 6 year: 2019 ident: 2024012714033572800_jbmr4480-bib-0018 article-title: Clinical impact of RANK signalling in ovarian cancer publication-title: Cancers doi: 10.3390/cancers11060791 – volume: 28 start-page: 412 issue: 2 year: 2018 ident: 2024012714033572800_jbmr4480-bib-0034 article-title: Sarcopenia and skeletal muscle quality as predictors of postoperative complication and early mortality in gynecologic cancer publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0000000000001157 – volume: 29 start-page: 15 issue: 1 year: 2013 ident: 2024012714033572800_jbmr4480-bib-0043 article-title: STAR: ultrafast universal RNA-seq aligner publication-title: Bioinformatics doi: 10.1093/bioinformatics/bts635 – reference: 35067972 - J Bone Miner Res. 2022 Mar;37(3):379-380 |
| SSID | ssj0006566 |
| Score | 2.489332 |
| Snippet | ABSTRACT
Tumor‐ and bone‐derived soluble factors have been proposed to participate in the alterations of skeletal muscle size and function in cachexia. We... Tumor- and bone-derived soluble factors have been proposed to participate in the alterations of skeletal muscle size and function in cachexia. We previously... Tumor‐ and bone‐derived soluble factors have been proposed to participate in the alterations of skeletal muscle size and function in cachexia. We previously... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 381 |
| SubjectTerms | Animals Antineoplastic drugs ANTIRESORPTIVE TREATMENTS Antitumor agents Atrophy Bisphosphonates Body composition BONE Bone Diseases, Metabolic - pathology Bone loss Bone mass Bone resorption Bone tumors Bone turnover CACHEXIA Cachexia - complications Cachexia - drug therapy CANCER Collagen Drug development Female Humans Ligands Metastases Metastasis Mice MUSCLE Muscle, Skeletal - pathology Muscular Atrophy - pathology Musculoskeletal system Myotubes Ovarian cancer Ovarian Neoplasms - complications Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology RANKL Skeletal muscle Therapeutic targets TRANCE protein |
| Title | RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non‐Metastatic Ovarian Cancer in Mice |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjbmr.4480 https://www.ncbi.nlm.nih.gov/pubmed/34904285 https://www.proquest.com/docview/2640907674 https://www.proquest.com/docview/2610081199 https://pubmed.ncbi.nlm.nih.gov/PMC8940654 |
| Volume | 37 |
| WOSCitedRecordID | wos000729624000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1523-4681 dateEnd: 20231231 omitProxy: false ssIdentifier: ssj0006566 issn: 0884-0431 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1523-4681 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006566 issn: 0884-0431 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB4tXQ5ceC2PwLIyCCEuYRPHqRNxahcqHm1A1SJ6y9qOIwKsi9ruir3xE_iN_BJmkjRQLUhI3BJ5rPgxM55xZr4BeKiRZ21fCT9Iyr4vRFz6iZGFH_FEq1SlRkaqLjYhsyyZzdK3W_B0nQvT4EN0F24kGbW-JgFXern_CzT0oz5ePEHnAv31bY58G_dg-9l09G7cKWIyVRojkmItonANLBTw_a7z5nF0zsY8Hyr5uwlbn0GjK_81-qtwuTU92aDhlWuwZd112Bk4dLuPz9gjVgeD1rfsO3A0HWSvx2yIR90nVVg2JYRXu2QHhP_8tVJMuYIN586yMU6LUQEQYwumz1g2dz--fZ_YlaJcpcqwN6fojiuHXZG_FqxybILK6QYcjp4fHrzw22IMvhEiQl1t0n6B3o0t0AhUXFppY44aIlC81EqGWpWxVAZ1pxKRNYoHBW6AlGUobGpsdBN6Dkd1GxhZIJIunExpBC8Spa02VvIy1sYIE3nweL0luWmByqlexue8gVjmOS1eTovnwYOO9EuDzvEnot31vuatgC5ztAODNCAkIw_ud80oWvS_RDk7PyEaQj4KwzT14FbDBt1XIpGStxl7IDcYpCMg2O7NFld9qOG7k1RQRi9Os2aQvw88fzWcTOnhzr-T3oVLnBI06ii5XeitFif2Hlw0p6tqudiDC3KW7LVygm_vX2Y_AWhTGPs |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fb9MwED9NAwle-Df-BAYYhBAvYYnj1LHESzsxbawNqKrE3jLbcUSAuajtJvbGR-Az8km4S9pANZCQeIvks-LYd-ffOeffATwzqLOup0UYZVUvFCKtwszKMkx4ZrTSyspEN8UmZJ5nR0fq3Qa8Wt2FafkhugM3sozGX5OB04H0zi_W0I_mZPYSowsM2C8JBBpUuOH9Qd75YUIqLYakVIskXvEKRXyn67q-G12AmBczJX9HsM0WtHf9_wZ_A64toSfrt7pyEzacvwVbfY9h98k5e86aZNDmlH0Ljsf9_HDIBrjVfdKlY2NieHVztkv8z19rzbQv2WDqHRvidzEqAGJdycw5y6f-x7fvI7fQdFeptuztGYbj2mNX1K8Zqz0boXO6DZO915Pd_XBZjCG0QiToq63qlRjduBJBoObSSZdy9BCR5pXRMja6SqW26Du1SJzVPCpxBaSsYuGUdckd2PQ4qnvACIFIOnCylRW8zLRxxjrJq9RYK2wSwIvVmhR2SVRO9TI-Fy3FMi9o8gqavACedqJfWnaOPwltrxa2WBrovEAcGKmImIwCeNI1o2nR_xLt3fSUZIj5KI6VCuBuqwfdWxKhKNpMA5BrGtIJEG33eouvPzT03ZkSdKMXP7PRkL8PvHgzGI3p4f6_iz6GK_uT0bAYHuSHD-Aqp8saTcbcNmwuZqfuIVy2Z4t6PnvUGMtPfBQZxg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fb9MwED9NHUK88G_8CQwwCCFewhLHqWOJl3ajAtaGqRrS3oLjOCLA3KntJvbGR-Az8km4S9JANZCQeIvks-LYd-ffOeffATzNUWdtXws_SMq-L0Rc-omRhR_xJNdKKyMjXRebkGmaHB2pgw14uboL0_BDdAduZBm1vyYDtydFufOLNfRTfjx_gdEFBuybgorI9GBzbzp6P-48MWGVBkVSskUUrpiFAr7TdV7fjy6AzIu5kr9j2HoTGl37v-Ffh6st-GSDRltuwIZ1N2Fr4DDwPj5nz1idDlqfs2_Bh-kg3R-zIW52n3Vh2ZQ4Xu2C7RID9NdKM-0KNpw5y8b4XYxKgBhbsPycpTP349v3iV1quq1UGfbuDANy7bAraticVY5N0D3dgsPRq8Pd135bjsE3QkTorY3qFxjf2AJhoObSShtz9BGB5mWuZZjrMpbaoPfUIrJG86DAFZCyDIVVxka3oedwVHeBEQaRdORkSiN4kejc5sZKXsa5McJEHjxfrUlmWqpyqpjxJWtIlnlGk5fR5HnwpBM9afg5_iS0vVrYrDXRRYZIMFABcRl58LhrRuOiPyba2dkpyRD3URgq5cGdRg-6t0RCUbwZeyDXNKQTIOLu9RZXfawJvBMl6E4vfmatIX8fePZ2OJnSw71_F30Elw_2Rtn4Tbp_H65wuq1Rp8xtQ285P7UP4JI5W1aL-cPWWn4CUZIabw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=RANKL+Blockade+Reduces+Cachexia+and+Bone+Loss+Induced+by+Non%E2%80%90Metastatic+Ovarian+Cancer+in+Mice&rft.jtitle=Journal+of+bone+and+mineral+research&rft.au=Pin%2C+Fabrizio&rft.au=Jones%2C+Alexander+J&rft.au=Huot%2C+Joshua+R&rft.au=Narasimhan%2C+Ashok&rft.date=2022-03-01&rft.pub=Oxford+University+Press&rft.issn=0884-0431&rft.eissn=1523-4681&rft.volume=37&rft.issue=3&rft.spage=381&rft.epage=396&rft_id=info:doi/10.1002%2Fjbmr.4480&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0884-0431&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0884-0431&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0884-0431&client=summon |